FRANKLIN LAKES, N.J., July 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share.About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving me ...

Becton Dickinson (BDX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a ch ...

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate r ...

Shares of Becton, Dickinson and Company (BDX) , popularly known as BD, have gained 0.9% since Jul 10, after the company announced reduced availability of blood culture vials due to issues with its supplier. The rise could be likely due to immediate measures taken by the company to mitigate this supply disruption, including leveraging its manufacturing expertise and collaborating with the FDA.The FDA issued a letter last week to healthcare providers highlighting the supply shortage, underscoring the critical ...

If you can count, you may find healthcare stocks focused on the aging population to be a compelling opportunity. What do I mean? When it comes to the senior care sector, the fundamental argument comes down to one word repeated three times: demographics, demographics, demographics.According to the U.S. Census Bureau, the “U.S. population age 65 and over grew nearly five times faster than the total population over the 100 years from 1920 to 2020.” Not only that, the older population reached 55.8 million, repr ...

文章核心观点 - 公司正在采取各种措施应对血培养瓶供应问题,包括与供应商合作、调整生产计划、与FDA合作等 [1][2][3][4] - 公司正在手动分配血培养瓶,以尽量减少对患者护理的影响 [3] - 这一供应问题预计不会对公司财务产生重大影响 [4] 公司概况 - 公司是全球领先的医疗技术公司,致力于推动医疗诊断和治疗的进步 [5] - 公司拥有70,000名员工,在全球范围内与各方合作,共同应对全球健康挑战 [5] 供应问题应对措施 - 与供应商合作,提供制造技术支持,以加快生产 [1] - 使用空运方式运输,缩短供应周期 [1] - 调整公司内部生产计划,加快血培养瓶的生产 [1] - 与FDA合作,评估所有可能的缓解供应延迟的选择 [1] - 之前的玻璃瓶供应商已重启生产,帮助填补供应缺口 [1] 客户指引 - 建议客户根据临床需求,优先使用血培养瓶,并参考相关指南 [3]

FRANKLIN LAKES, N.J., July 10, 2024  /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has surpassed its Scope 1 and 2 science-based greenhouse gas (GHG) emissions reduction targets for FY 2023 by 5 percentage points and received approval for near and long-term science-based emissions reduction targets from the Science Based Target initiative (SBTi)[1]. This furthers the company's progress toward its goal to reach net zero GHG emi ...

Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced the commercial launch of a new single-cell research tool, BD Rhapsody ATAC-Seq Assay. The tool is intended to help scientists better understand how the molecular machinery within a cell function and how it regulates changes in a cell that can lead to cancer and other diseases. More on the News Single-cell studies of various areas of health and disease are currently being conducted by researchers worldwide utilizing novel methodo ...

BD Rhapsody™ ATAC-Seq Assay Helps Researchers Understand DNA Regulation and Enable Advancements in Precision Medicine FRANKLIN LAKES, N.J., June 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases. Commercial ...

FRANKLIN LAKES, N.J., June 20, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to discuss quarterly financial results on the following dates: Third Quarter Fiscal 2024 —Thursday, August 1, 2024 at 8:00 a.m. (ET) Fourth Quarter Fiscal 2024 — Thursday, November 7, 2024 at 8:00 a.m. (ET) BD will issue a detailed announcement prior to each quarter's webcast, confirming the date and time of the earnin ...